AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

AstraZeneca (NASDAQ: NASDAQ:AZN) said Tuesday it could be fined up to $8 million by Chinese authorities over allegedly unpaid import taxes. Concerning the illegal drug importation allegations ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program ...

AstraZeneca AZN-1.55%decrease; red down pointing triangle posted increased core earnings per share and sales for the first quarter but warned of mounting legal challenges in China. The British ...

AstraZeneca has rejoined PhRMA as it expands its “presence in the United States with significant investments in research, development and manufacturing,” Pascal Soriot, AZ’s CEO, said in a ...

On Thursday, May 8, 2025, a three-judge panel of the Third Circuit affirmed the district court’s rejection of AstraZeneca’s constitutional and regulatory challenge to the Negotiation Program.